Joris van de Haar
The Netherlands Cancer Institute · 112 works · 4,189 citations · h-index 19
Top works
- Caring for patients with cancer in the COVID-19 era
- Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids
- Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients
- MHC-I Genotype Restricts the Oncogenic Mutational Landscape
- γδ T cells are effectors of immunotherapy in cancers with HLA class I defects
- Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
- A pan-cancer analysis of the microbiome in metastatic cancer
- Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
- Limited evolution of the actionable metastatic cancer genome under therapeutic pressure
- Identifying Epistasis in Cancer Genomes: A Delicate Affair
- Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
- Prospective experimental treatment of colorectal cancer patients based on organoid drug responses
- Advancing molecular tumour boards: highly needed to maximise the impact of precision medicine
- Functional precision oncology using patient-derived assays: bridging genotype and phenotype
- ESMO Recommendations on clinical reporting of genomic test results for solid cancers
- ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice
- Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma
- The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)
- Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
- Author Correction: Caring for patients with cancer in the COVID-19 era